Is Marker Therapeutics, Inc. (MRKR) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 83.4% / 30% | 10.2% / 30% | 6.63% / 5% | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 83.4% / 33% | 10.2% / 33% | 6.63% / 5% | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 87.1% / 33% | 10.7% / 33% | 6.63% / 5% | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 83.4% / 33% | 10.2% / 33% | 6.63% / 5% | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 87.1% / 33% | 10.7% / 50% | 6.63% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -232.7% | |
| Operating Margin | -170.7% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -68.8% | |
| Return on Assets (ROA) | -37.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$11M |
| Free Cash Flow | -$11M |
| Current Ratio | 8.4 |
| Total Assets | $22M |
Price & Trading
| Last Close | $1.35 |
| 50-Day MA | $1.55 |
| 200-Day MA | $1.33 |
| Avg Volume | 311K |
| Beta | 1.5 |
|
52-Week Range
$0.81
| |
About Marker Therapeutics, Inc. (MRKR)
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Marker Therapeutics, Inc. (MRKR) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Marker Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Marker Therapeutics, Inc.'s debt ratio?
Marker Therapeutics, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Marker Therapeutics, Inc.'s key financial metrics?
Marker Therapeutics, Inc. has a market capitalization of $22M, and revenue of $7M. Return on equity stands at -68.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.